{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:22Z","timestamp":1788922162227,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"am","delay-in-days":278,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA041359"],"award-info":[{"award-number":["R01 DA041359"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA056581"],"award-info":[{"award-number":["R01 DA056581"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA013429"],"award-info":[{"award-number":["P30DA013429"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM147005"],"award-info":[{"award-number":["R35GM147005"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neuropharm.2025.110316","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T13:00:35Z","timestamp":1737637235000},"page":"110316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pharmacological characterization of the novel selective kappa opioid receptor agonists 10-Iodo-Akuammicine and 10-Bromo-akuammicine in mice"],"prefix":"10.1016","volume":"268","author":[{"given":"Kathryn","family":"Bland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6805-0984","authenticated-orcid":false,"given":"Conrad","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Creed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Noel-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-0597","authenticated-orcid":false,"given":"Andrew P.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5206-9497","authenticated-orcid":false,"given":"Lee-Yuan","family":"Liu-Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110316_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0016-5085(95)90287-2","article-title":"Aquaretic effect of the kappa-opioid agonist ru 51599 in cirrhotic rats with ascites and water retention","volume":"109","author":"Bosch-Marce","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2025.110316_bib2","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.1523\/JNEUROSCI.3769-07.2007","article-title":"Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria","volume":"27","author":"Bruchas","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110316_bib3","doi-asserted-by":"crossref","first-page":"18081","DOI":"10.1074\/jbc.M513640200","article-title":"Kappa opioid receptor activation of p38 mapk is grk3-and arrestin-dependent in neurons and astrocytes","volume":"281","author":"Bruchas","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110316_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/164_2020_395","article-title":"Biased ligands at the kappa opioid receptor: Fine-tuning receptor pharmacology","volume":"271","author":"Brust","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuropharm.2025.110316_bib6","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/acschemneuro.0c00407","article-title":"Comparison of pharmacological properties between the kappa opioid receptor agonist nalfurafine and 42b, its 3-dehydroxy analogue: Disconnect between in vitro agonist bias and in vivo pharmacological effects","volume":"11","author":"Cao","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110316_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1042\/BJ20141471","article-title":"Determination of sites of u50,488h-promoted phosphorylation of the mouse kappa opioid receptor (kopr): Disconnect between kopr phosphorylation and internalization","volume":"473","author":"Chen","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2025.110316_bib8","article-title":"Agonist-promoted phosphorylation and internalization of the kappa opioid receptor in mouse brains: Lack of connection with conditioned place aversion","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib9","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0028-20.2020","article-title":"Characterization of a knock-in mouse line expressing a fusion protein of kappa opioid receptor conjugated with tdtomato: 3-dimensional brain imaging via clarity","volume":"7","author":"Chen","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2025.110316_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0165-6147(86)90257-9","article-title":"In-vivo studies on kappa opioid receptors","volume":"7","author":"Cowan","year":"1986","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110316_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/acs.jnatprod.0c01036","article-title":"Isolation and pharmacological characterization of six opioidergic picralima nitida alkaloids","volume":"84","author":"Creed","year":"2021","journal-title":"J Nat Prod"},{"key":"10.1016\/j.neuropharm.2025.110316_bib12","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acschemneuro.9b00195","article-title":"Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses","volume":"10","author":"Dunn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110316_bib13","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0024-3205(99)00417-8","article-title":"Potent antinociceptive effects of trk-820, a novel kappa-opioid receptor agonist","volume":"65","author":"Endoh","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110316_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1995-7645(13)60182-0","article-title":"Medicinal uses, phytochemistry and pharmacology of picralima nitida (apocynaceae) in tropical diseases: a review","volume":"7","author":"Erharuyi","year":"2014","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.neuropharm.2025.110316_bib15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2025.110316_bib16","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c00736","article-title":"Discovery of potent kappa opioid receptor agonists derived from akuammicine","author":"Hennessy","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110316_bib17","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1039\/JR9270001950","article-title":"The alkaloids of picralima klaineana","volume":"1927","author":"Henry","year":"1927","journal-title":"Journal of the Chemical Society"},{"key":"10.1016\/j.neuropharm.2025.110316_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108860","article-title":"Agonist-promoted kappa opioid receptor (kor) phosphorylation has behavioral endpoint-dependent and sex-specific effects","volume":"202","author":"Huang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110316_bib19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuropharm.2025.110316_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1476-5381.1990.tb12110.x","article-title":"Ci-977, a novel and selective agonist for the kappa-opioid receptor","volume":"101","author":"Hunter","year":"1990","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/164_2020_399","article-title":"Kappa opioid agonist-induced diuresis: characteristics, mechanisms, and beyond","volume":"271","author":"Inan","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/164_2020_420","article-title":"Antipruritic effects of kappa opioid receptor agonists: Evidence from rodents to humans","volume":"271","author":"Inan","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine","volume":"371","author":"Kaski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuropharm.2025.110316_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00213-010-1819-6","article-title":"Kappa opioids and the modulation of pain","volume":"210","author":"Kivell","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110316_bib25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase iii, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.neuropharm.2025.110316_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-2999(96)00961-2","article-title":"Kappa-opioid receptor agonist u50,488h modulates cocaine and morphine self-administration in drug-naive rats and mice","volume":"321","author":"Kuzmin","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0014-2999(85)90431-5","article-title":"[3h]u-69593 a highly selective ligand for the opioid kappa receptor","volume":"109","author":"Lahti","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib28","doi-asserted-by":"crossref","first-page":"12087","DOI":"10.1074\/jbc.274.17.12087","article-title":"U50,488h-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation","volume":"274","author":"Li","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110316_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14656566.2020.1849142","article-title":"An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease","volume":"22","author":"Lipman","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.neuropharm.2025.110316_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108324","article-title":"Pharmacological and phosphoproteomic approaches to roles of protein kinase c in kappa opioid receptor-mediated effects in mice","volume":"181","author":"Liu","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110316_bib31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","article-title":"Phosphoproteomic approach for agonist-specific signaling in mouse brains: Mtor pathway is involved in kappa opioid aversion","volume":"44","author":"Liu","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110316_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao4927","article-title":"In vivo brain gpcr signaling elucidated by phosphoproteomics","volume":"360","author":"Liu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2025.110316_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.964724","article-title":"Signaling underlying kappa opioid receptor-mediated behaviors in rodents","volume":"16","author":"Liu-Chen","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110316_bib34","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1074\/jbc.M305796200","article-title":"Prolonged kappa opioid receptor phosphorylation mediated by g-protein receptor kinase underlies sustained analgesic tolerance","volume":"279","author":"McLaughlin","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110316_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-2999(98)00232-5","article-title":"Opioid activity of alkaloids extracted from picralima nitida (fam. Apocynaceae)","volume":"350","author":"Menzies","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/164_2020_400","article-title":"Clinical profiles of nalfurafine hydrochloride for the treatment of pruritus patients","volume":"271","author":"Miyamoto","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1248\/cpb.46.366","article-title":"Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan","volume":"46","author":"Nagase","year":"1998","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.neuropharm.2025.110316_bib38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1358\/dot.2009.45.5.1362067","article-title":"Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients","volume":"45","author":"Nakao","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.neuropharm.2025.110316_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0022-3565(24)36769-2","article-title":"Effects of kappa opioids on cocaine self-administration by rhesus monkeys","volume":"282","author":"Negus","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuropharm.2025.110316_bib40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00002826-199619050-00009","article-title":"Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain","volume":"19","author":"Pande","year":"1996","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2025.110316_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: an emerging paradigm in gpcr drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.neuropharm.2025.110316_bib43","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin a: a potent naturally occurring nonnitrogenous kappa opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2025.110316_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a g-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2025.110316_bib45","first-page":"563","article-title":"Differential effects of mu and kappa opioid systems on motivational processes","volume":"75","author":"Shippenberg","year":"1986","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2025.110316_bib46","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/emboj\/17.4.886","article-title":"Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist u-50,488h and attenuates morphine withdrawal","volume":"17","author":"Simonin","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2025.110316_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3565(25)33422-1","article-title":"U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist","volume":"224","author":"von Voigtlander","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2025.110316_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0022-3565(25)21012-6","article-title":"Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid","volume":"246","author":"von Voigtlander","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2025.110316_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002130100788","article-title":"Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans","volume":"157","author":"Walsh","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110316_bib50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","article-title":"Therapeutic potential of beta-arrestin- and g protein-biased agonists","volume":"17","author":"Whalen","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110316_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The g protein-biased kappa-opioid receptor agonist rb-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuropharm.2025.110316_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ceb.2013.10.008","article-title":"Recent developments in biased agonism","volume":"27","author":"Wisler","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.neuropharm.2025.110316_bib53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.drugalcdep.2013.08.021","article-title":"L-isocorypalmine reduces behavioral sensitization and rewarding effects of cocaine in mice by acting on dopamine receptors","volume":"133","author":"Xu","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2025.110316_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2021_443","article-title":"Preclinical studies on nalfurafine (trk-820), a clinically used kor agonist","volume":"271","author":"Zhou","year":"2022","journal-title":"Handb. Exp. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:20:47Z","timestamp":1778710847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082500022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":54,"alternative-id":["S002839082500022X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110316","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterization of the novel selective kappa opioid receptor agonists 10-Iodo-Akuammicine and 10-Bromo-akuammicine in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110316"}}